Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?

IF 2.8 3区医学 Q3 ONCOLOGY

Urologic Oncology-seminars and Original Investigations Pub Date : 2026-02-01 Epub Date: 2025-11-20 DOI:10.1016/j.urolonc.2025.11.004

Alexa Rose León B.S. , Michael Risk M.D., Ph.D. , William A. Ricke Ph.D. , Jinn-ing Liou M.S. , David F. Jarrard M.D. , Kyle A. Richards M.D.

{"title":"Understanding the role of statin use on advanced prostate cancer outcomes: Does the statin type, cumulative dose, or duration impact survival?","authors":"Alexa Rose León B.S. , Michael Risk M.D., Ph.D. , William A. Ricke Ph.D. , Jinn-ing Liou M.S. , David F. Jarrard M.D. , Kyle A. Richards M.D.","doi":"10.1016/j.urolonc.2025.11.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To further investigate the association of improved survival in men with prostate cancer (PCa) on androgen deprivation therapy (ADT), we hypothesized that increased duration and dose of statin in men with PCa on ADT would show a greater effect.</div></div><div><h3>Methods</h3><div>Using Veterans Affairs databases, we identified all men diagnosed with PCa between 2000 and 2008 that were treated with ADT with follow-up through May 2016. Exclusions included treatment with ADT or statins for ≤6 months or ADT receipt concurrently with localized radiation. Patients were stratified by cumulative duration of statin use <36 or ≥36 months, and we adjusted for cumulative dose and statin type. Cox proportional hazards ratios were calculated for overall survival (OS) and cancer-specific survival (CSS) after propensity score adjustment.</div></div><div><h3>Results</h3><div>The cohort after exclusions consisted of 52,763 patients: 32% had a cumulative duration use of statins <36 months. Our analysis for OS showed improved survival in the ≥36 months group (HR 0.60, 95% CI 0.57–0.63), the highest cumulative dose group (HR 0.90, 95% CI 0.82–0.99), and hydrophilic group (HR 0.58, 95% CI 0.54–0.62). In our competing risks analysis for CSS, we noted improved survival in the ≥36 months group (HR 0.83, 95% CI 0.73–0.95) and the highest cumulative dose group (HR 0.74, 95% CI 0.59–0.93), but statin type was not associated with improved survival (HR 0.82, 95% CI 0.66–1.01).</div></div><div><h3>Conclusions</h3><div>We show a strong minimum effective dose/duration type relationship with statin use in Veterans with PCa receiving ADT.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"44 2","pages":"Pages 125.e23-125.e31"},"PeriodicalIF":2.8000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1078143925004508","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To further investigate the association of improved survival in men with prostate cancer (PCa) on androgen deprivation therapy (ADT), we hypothesized that increased duration and dose of statin in men with PCa on ADT would show a greater effect.

Methods

Using Veterans Affairs databases, we identified all men diagnosed with PCa between 2000 and 2008 that were treated with ADT with follow-up through May 2016. Exclusions included treatment with ADT or statins for ≤6 months or ADT receipt concurrently with localized radiation. Patients were stratified by cumulative duration of statin use <36 or ≥36 months, and we adjusted for cumulative dose and statin type. Cox proportional hazards ratios were calculated for overall survival (OS) and cancer-specific survival (CSS) after propensity score adjustment.

Results

The cohort after exclusions consisted of 52,763 patients: 32% had a cumulative duration use of statins <36 months. Our analysis for OS showed improved survival in the ≥36 months group (HR 0.60, 95% CI 0.57–0.63), the highest cumulative dose group (HR 0.90, 95% CI 0.82–0.99), and hydrophilic group (HR 0.58, 95% CI 0.54–0.62). In our competing risks analysis for CSS, we noted improved survival in the ≥36 months group (HR 0.83, 95% CI 0.73–0.95) and the highest cumulative dose group (HR 0.74, 95% CI 0.59–0.93), but statin type was not associated with improved survival (HR 0.82, 95% CI 0.66–1.01).

Conclusions

We show a strong minimum effective dose/duration type relationship with statin use in Veterans with PCa receiving ADT.

查看原文本刊更多论文

了解他汀类药物在晚期前列腺癌预后中的作用：他汀类药物的类型、累积剂量或持续时间是否影响生存？

目的：为了进一步研究雄激素剥夺治疗（ADT）与前列腺癌（PCa）患者生存率的关系，我们假设增加他汀类药物对前列腺癌患者ADT治疗的持续时间和剂量会产生更大的影响。方法：使用退伍军人事务数据库，我们确定了2000年至2008年间诊断为PCa的所有接受ADT治疗的男性，随访至2016年5月。排除包括ADT或他汀类药物治疗≤6个月或ADT同时接受局部放疗。结果：排除后的队列包括52,763例患者：32%的患者累积使用他汀类药物的时间。结论：我们显示，在接受ADT的PCa退伍军人中，他汀类药物的最小有效剂量/持续时间类型与他汀类药物的使用有很强的关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologic Oncology-seminars and Original Investigations 医学-泌尿学与肾脏学

CiteScore

4.80

自引率

3.70%

发文量

297

审稿时长

7.6 weeks

期刊介绍： Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.